Literature DB >> 18436406

Magnetic resonance imaging features of fibrocystic change of the breast.

Jeon-Hor Chen1, Hui Liu, Hyeon-Man Baek, Orhan Nalcioglu, Min-Ying Su.   

Abstract

PURPOSE: Studies specifically reporting MRI of fibrocystic change (FCC) of the breast are very few and its MRI features are not clearly known. The purpose of this study was to analyze the MRI features of FCC of the breast.
MATERIALS AND METHODS: Thirty-one patients with pathologically proven FCC of the breast were retrospectively reviewed. The MRI study was performed using a 1.5-T MR scanner with standard bilateral breast coil. The imaging protocol consisted of pre-contrast T1-weighed imaging and dynamic contrast-enhanced axial T1-weighed imaging. The MRI features were interpreted based on the morphologic and enhancement kinetic descriptors defined on ACR BIRADS-MRI lexicon.
RESULTS: FCC of the breast had a wide spectrum of morphologic and kinetic features on MRI. Two types of FCC were found, including a more diffuse type of nonmass lesion (12/31, 39%) showing benign enhancement kinetic pattern with medium wash-in in early phase (9/10, 90%) and a focal mass-type lesion (11/31, 35%) with enhancement kinetic usually showing rapid up-slope mimicking a breast cancer (8/11, 73%).
CONCLUSION: MRI is able to elaborate the diverse imaging features of FCC of the breast. Our result showed that FCC presenting as a focal mass-type lesion was usually overdiagnosed as malignancy. Understanding MRI of FCC is important to determine which cohort of patients should be followed up alone or receive aggressive management.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18436406      PMCID: PMC2613187          DOI: 10.1016/j.mri.2008.02.004

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  22 in total

1.  Mammographic and sonographic appearances of nodular adenosis.

Authors:  P J DiPiro; J A Gulizia; S C Lester; J E Meyer
Journal:  AJR Am J Roentgenol       Date:  2000-07       Impact factor: 3.959

2.  Magnetic resonance imaging characteristics of fibrocystic change of the breast.

Authors:  Maurice A A J van den Bosch; Bruce L Daniel; Michelle N Mariano; Kent N Nowels; Robyn L Birdwell; Kathy J Fong; Pam S Desmond; Sylvia Plevritis; Lara A Stables; Marowan Zakhour; Robert J Herfkens; Debra M Ikeda
Journal:  Invest Radiol       Date:  2005-07       Impact factor: 6.016

3.  Apocrine metaplasia: mammographic and sonographic appearances.

Authors:  J K Warner; D Kumar; W A Berg
Journal:  AJR Am J Roentgenol       Date:  1998-05       Impact factor: 3.959

4.  Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy.

Authors:  K A Kvistad; I J Bakken; I S Gribbestad; B Ehrnholm; S Lundgren; H E Fjøsne; O Haraldseth
Journal:  J Magn Reson Imaging       Date:  1999-08       Impact factor: 4.813

5.  Does size matter? Positive predictive value of MRI-detected breast lesions as a function of lesion size.

Authors:  Laura Liberman; Gary Mason; Elizabeth A Morris; D David Dershaw
Journal:  AJR Am J Roentgenol       Date:  2006-02       Impact factor: 3.959

6.  A case-control study of risk factors for fibrocystic breast conditions: Shanghai Nutrition and Breast Disease Study, China, 1995-2000.

Authors:  Chunyuan Wu; Roberta M Ray; Ming Gang Lin; Dao Li Gao; Neilann K Horner; Zakia C Nelson; Johanna W Lampe; Yong Wei Hu; Jackilen Shannon; Helge Stalsberg; Wenjin Li; Dawn Fitzgibbons; Peggy Porter; Ruth E Patterson; Jessie A Satia; David B Thomas
Journal:  Am J Epidemiol       Date:  2004-11-15       Impact factor: 4.897

7.  Pharmacokinetic parameters analyzed from mr contrast enhancement kinetics of multiple malignant and benign breast lesions detected in the same patients.

Authors:  Min-Y Su; Hon J Yu; Phillip M Carpenter; Christine E McLaren; Orhan Nalcioglu
Journal:  Technol Cancer Res Treat       Date:  2005-06

8.  Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.

Authors:  Laura Esserman; Nola Hylton; Tracy George; Noel Weidner
Journal:  Breast J       Date:  1999-01       Impact factor: 2.431

9.  Sonographic findings in focal fibrocystic changes of the breast.

Authors:  Mahesh K Shetty; Yogesh P Shah
Journal:  Ultrasound Q       Date:  2002-03       Impact factor: 1.657

10.  MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer.

Authors:  Constance D Lehman; Constantine Gatsonis; Christiane K Kuhl; R Edward Hendrick; Etta D Pisano; Lucy Hanna; Sue Peacock; Stanley F Smazal; Daniel D Maki; Thomas B Julian; Elizabeth R DePeri; David A Bluemke; Mitchell D Schnall
Journal:  N Engl J Med       Date:  2007-03-28       Impact factor: 91.245

View more
  5 in total

Review 1.  Pearls and pitfalls in breast MRI.

Authors:  I Millet; E Pages; D Hoa; S Merigeaud; F Curros Doyon; X Prat; P Taourel
Journal:  Br J Radiol       Date:  2011-11-29       Impact factor: 3.039

2.  Usefulness of diffusion-weighted imaging of breast tumors: quantitative and visual assessment.

Authors:  Kaiji Inoue; Eito Kozawa; Waka Mizukoshi; Junji Tanaka; Toshiaki Saeki; Takaki Sakurai; Fumiko Kimura
Journal:  Jpn J Radiol       Date:  2011-07-24       Impact factor: 2.374

3.  Stromal fibrosis: imaging features with diagnostic contribution of diffusion-weighted MRI.

Authors:  Ravza Yilmaz; Zuhal Bayramoglu; Merve Gulbiz Kartal; Emine Çaliskan; Artur Salmaslıoglu; Memduh Dursun; Gulden Acunas
Journal:  Br J Radiol       Date:  2018-02-16       Impact factor: 3.039

4.  Significance of breast lesion descriptors in the ACR BI-RADS MRI lexicon.

Authors:  Garima Agrawal; Min-Ying Su; Orhan Nalcioglu; Stephen A Feig; Jeon-Hor Chen
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

5.  Breast Dynamic Contrast Enhanced MRI: Fibrocystic Changes Presenting as a Non-mass Enhancement Mimicking Malignancy.

Authors:  Zorica C Milosevic; Mirjan M Nadrljanski; Zorka M Milovanovic; Nina Z Gusic; Slavko S Vucicevic; Olga S Radulovic
Journal:  Radiol Oncol       Date:  2017-05-07       Impact factor: 2.991

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.